BioMedNewsBreaks

ThursdayAug 22, 2024 2:48 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Upcoming Virtual Investor CEO Connect Segment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be spotlighted in this month’s Virtual Investor CEO Connect. According to the announcement CNS Pharmaceuticals CEO John Climaco will participate in a live moderated webcast to begin at 12 p.m. ET on Aug. 26, 2024. During the webcast, Climaco will present a brief overview of the company; the webcast also includes a live question-and-answer segment.  a brief presentation, followed by an interactive Q&A session. A replay of the webcast will be available on…

Continue Reading

ThursdayAug 22, 2024 2:31 pm

BioMedNewsBreaks — PaxMedica Inc. (PXMD) Committed to Global Health, Potential Positive Impact of PAX-101

PaxMedica (OTC: PXMD), a biopharmaceutical company specializing in neurological disorder treatments, is preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration for suramin to treat Human African Trypanosomiasis (“HAT”). “In April 2024, PaxMedica underscored its commitment to global health by responding to an urgent request from Malawi for an emergency release of suramin, demonstrating its dedication to advancing healthcare solutions. PaxMedica will have a crucial Type C meeting with the FDA, pivotal to the progress of PAX-101, its leading drug candidate for autism treatment, within the regulatory framework… This meeting is a significant event…

Continue Reading

WednesdayAug 21, 2024 10:58 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), EIB Close on Loan Restructuring Agreement

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, has closed on its previously announced loan restructuring agreement. According to the announcement, the agreement is with the European Investment Bank (“EIB”) and includes an amendment. Specifically, the agreement notes that “in connection with the transaction, an amount equal to approximately EUR 26.6 million (equal to approximately $29 million), including interest accrued to date, owed by the company to the EIB under the finance contract was converted into 1,000 preferred shares, no…

Continue Reading

WednesdayAug 21, 2024 9:36 am

BioMedNewsBreaks — GeoVax Labs Inc. (NASDAQ: GOVX) Enters $8.5M Registered Direct Offering with Institutional Investor

GeoVax Labs (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, has entered into a definitive securities purchase agreement with a certain institutional investor. The agreement is for the purchase and sale of 1,700,000 shares of the company’s common stock (or common stock equivalents), offered at $5 per share as part of a registered direct offering. The company will also issue the investor(s), in a concurrent private placement, warrants to purchase up to 1,700,000 shares of common stock. The exercise price of the warrants is also $5 per share. The warrants will be exercisable…

Continue Reading

TuesdayAug 20, 2024 1:30 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Into $2M Investment Commitment Agreement with Its Largest Existing Shareholder

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, has entered into a $2 million Investment Commitment Agreement with RK Stone Miami LLC, an affiliate of the largest shareholder of the company, Mr. Daniel Stone. Under the terms of the agreement, Scinai may issue and sell ASDs to the investor, from time to time through December 31, 2024, for an aggregate purchase price of up to $2 million. The agreement does not require the company to register for resale the ADSs to be…

Continue Reading

TuesdayAug 20, 2024 11:21 am

BioMedNewsBreaks — InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Exciting INM-901 Data Providing ‘Attractive Therapeutic Approach’ in Alzheimer’s Treatment

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced that recent data from preclinical studies confirms INM-901, a proprietary small molecule drug candidate, as an oral formulation that will be utilized in the company’s development programs for Alzheimer’s disease. The data shows that the INM-901 formulation can be administered orally and maintains similar drug exposure and therapeutic levels as intraperitoneal (“IP”) delivery over a 24-hour period in the brain. The announcement noted that the oral delivery method offers potential advantages such as lower treatment delivery costs. “We are…

Continue Reading

MondayAug 19, 2024 10:39 am

BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion

Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, has released a business status update. According to the update, which outlines key 2024 progress, the company continues to move forward on developing and advancing its lead candidate, ONP-002, for the treatment of concussion. Specifically, the update noted that phase 2 human trials are slated to begin in the fourth quarter of this year. In addition to preparing for the upcoming phase 2 clinical trials, highlights of the report included the stability of ONP-002 across a wide temperature range, improvements in drug…

Continue Reading

FridayAug 16, 2024 3:26 pm

BioMedNewsBreaks — InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089 Showing Great Promise in Treating AMD

InMed Pharmaceuticals (NASDAQ: INM), a clinical stage company developing a pipeline of pharmaceutical drug candidates to treat several diseases with a high unmet medical need, is at the forefront of developing innovative treatment for age-related macular degeneration (“AMD”), with its flagship product INM-089 showing great promise. “AMD is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula… AMD is the leading cause of vision loss among people aged 50 and older. It comes in two forms: dry AMD, which is more common and less severe,…

Continue Reading

FridayAug 16, 2024 9:58 am

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Announces Q2, H1 2024 Financial Results Reflecting Efforts to Streamline Operations

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, today announced financial results for its Q2 and H1 2024 ending June 30, 2024. The announcement noted that the company achieved significant cost reductions, leading to an 8% quarter-over-quarter improvement in its loss from operations to $1.08 million in Q2 2024 from $1.18 million in Q1 2024. This improvement reflects HealthLynked’s ongoing efforts to streamline operations and transition its revenue streams from legacy clinical operations to app-based services. In addition, the company reported revenue of $0.78 million in Q2 2024 and $1.80 million in H1 2024. Its total operating expenses decreased by…

Continue Reading

ThursdayAug 15, 2024 12:32 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q2 2024 Financial Report, Operational Update

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, is reporting on financial and operations results for its second quarter 2024, the period that ended June 30, 2024. Highlights of the report include steady progress made toward key clinical and regulatory milestones on its HeartBeam AIMIGo(TM) System, including the 510(k) submission to the U.S. Food and Drug Administration (FDA); the report also noted that the company has completed two presubmission meetings with the FDA regarding the company’s planned 510(k) submission of its 12-lead synthesis software. “The second quarter of 2024 was…

Continue Reading